C9orf125 Inhibitors
C9orf125 inhibitors are a class of chemical compounds that exert their effects through various signaling pathways, ultimately leading to the decreased activity of C9orf125. These inhibitors target pivotal signaling molecules such as phosphoinositide 3-kinases (PI3K) and AKT, both of which are integral to the post-translational modification and GPI-anchor biosynthesis pathways. The inhibition of PI3K by specific flavonoids or synthetic compounds disrupts the downstream AKT signaling, which is a critical pathway for the normal function of C9orf125. Furthermore, compounds that inhibit mTOR, which is a downstream target of PI3K/AKT, also contribute to the indirect inhibition of C9orf125 by affecting the cellular processes it is involved in, including the post-GPI attachment process.
In addition to the PI3K/AKT/mTOR axis, other inhibitors impact the MAPK/ERK and p38 MAPK pathways. By doing so, they disturb necessary cellular signaling that governs post-translational modifications, which C9orf125 is reliant upon. The MEK inhibitors, for instance, interfere with the MAPK/ERK pathway, while p38 MAPK inhibitors disrupt a different aspect of the MAPK pathway. Both of these mechanisms result in an indirect inhibition of C9orf125 activity. The precise targeting of these signaling pathways by these inhibitors ensures that the activity of C9orf125 is modulated through the disruption of necessary signaling events, thus leading to a decrease in its functional activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
This flavonoid inhibits phosphoinositide 3-kinases (PI3K), which are involved in multiple signaling pathways including those that regulate post-translational modifications. C9orf125, involved in post-GPI attachment to proteins, relies on proper signaling for its function, and inhibition of PI3K can lead to altered GPI-anchor protein functionality. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As a potent PI3K inhibitor, Wortmannin disrupts the PI3K/AKT pathway which is crucial for multiple cellular processes. By inhibiting this pathway, the cellular environment and processes necessary for C9orf125 activity are affected, leading to reduced functionality. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This chemical is a PI3K inhibitor that blocks the AKT signaling pathway, crucial for post-translational modifications. C9orf125 function is dependent on the integrity of these pathways, and their disruption by LY 294002 inhibits its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the AKT signaling pathway, which is necessary for normal post-translational modification processes. The activity of C9orf125 is indirectly inhibited due to the interruption of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR is a downstream target of PI3K/AKT signaling, its inhibition can affect the processes that C9orf125 is involved in, specifically in post-translational modifications and the GPI anchor biosynthesis pathway. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
This alkylphospholipid inhibits the AKT pathway. By doing so, it disrupts downstream signaling events that are critical for the function of C9orf125 in the post-GPI attachment to proteins. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
As a tyrosine kinase inhibitor, Genistein disrupts various signaling pathways, including those involving post-translational modifications. This can lead to compromised activity of C9orf125 due to its role in GPI-anchor protein modification. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This MEK inhibitor interferes with the MAPK/ERK pathway, which can impact various cellular processes including those regulating post-translational modifications, subsequently leading to the decreased activity of C9orf125. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an MEK inhibitor that disrupts the MAPK/ERK pathway. This disruption can affect the functional activity of C9orf125, as it is reliant on intact signaling for its role in post-translational modifications. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB 203580 can inhibit the signaling pathways involved in stress responses and post-translational modifications. This may result in a decreased activity of C9orf125 due to the disruption of signaling necessary for its function. | ||||||